TIDMWDC
RNS Number : 8984S
WideCells Group PLC
28 June 2018
28 June 2018
WideCells Group PLC ('WideCells Group' or 'the Group')
Result of General Meeting
WideCells Group PLC, the healthcare services company focused on
providing stem cell services and ground-breaking insurance for stem
cell treatment, is pleased to announce that following the Group's
General Meeting held earlier today, all resolutions were duly
passed. As a result, the Placing (see announcements dated 10 May
2018, 5 June 2018, 11 June 2018 and 12 June 2018 for further
information) is now unconditional, save for Admission.
An application has been made for admission of a total of
68,698,355 new ordinary shares of GBP0.0025 (Ordinary Shares) each,
(being 67,865,022 Placing Shares and 833,333 Fee Shares, as set out
in the Company's prospectus dated 12 June 2018) on the Official
List of the FCA and to trading on the London Stock Exchange's main
market for listed securities (Admission). Admission is expected to
take place at 8.00 am on 29 June 2018.
Following Admission, the Company's total issued share capital
will consist of 133,519,365 Ordinary Shares. As each ordinary share
carries one vote the total number of voting rights attached to the
ordinary shares in the Company is 133,519,365.
This figure may be used by shareholders as the denominator for
the calculations by which they will determine if they are required
to notify their interest in ordinary shares in the Company in
accordance with the Disclosure Guidance and Transparency Rules of
the Financial Conduct Authority.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the person discharging managerial
responsibilities / person closely associated
--- -----------------------------------------------------------------------------------------------------------------
a) Names Peter Presland
João Andrade
Lopes Gil
Peter Hollands
David Bridgland
Marilyn Orcharton
Malcolm Glaister
David Henriques
--- ----------------------------------------- ----------------------------------------------------------------------
2 Reason for the notification
Increases in interests in ordinary shares
--- -----------------------------------------------------------------------------------------------------------------
a) Position/status Directors of the Company
--- ----------------------------------------- ----------------------------------------------------------------------
b) Initial notification /Amendment Initial notification
--- ----------------------------------------- ----------------------------------------------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- -----------------------------------------------------------------------------------------------------------------
a) Name WideCells Group PLC
--- ----------------------------------------- ----------------------------------------------------------------------
b) LEI n/a
--- ----------------------------------------- ----------------------------------------------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- -----------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, Ordinary shares of GBP0.0025 each
type of instrument
--- ----------------------------------------- ----------------------------------------------------------------------
b) Identification code GB00BD060S65
--- ----------------------------------------- ----------------------------------------------------------------------
c) Nature of the transaction Placing
--- ----------------------------------------- ----------------------------------------------------------------------
d) Price(s) and volume(s) Name Price(s) Volume(s)
------------------- --------- -----------
Peter Presland
João 3p 1,666,667
Andrade 3p 333,333
Lopes Gil 3p 266,667
Peter Hollands 3p 166,667
David Bridgland 3p 1,666,667
Marilyn Orcharton 3p 166,667
Malcolm Glaister 3p 500,000
David Henriques 3p 1,333,333
--- ----------------------------------------- ----------------------------------------------------------------------
d) Aggregated information 6,100,001
- Aggregated volume GBP183,000 (6,100,001 new ordinary shares at 3 pence per new
- Price ordinary share)
--- ----------------------------------------- ----------------------------------------------------------------------
e) Date of the transaction 29 June 2018
--- ----------------------------------------- ----------------------------------------------------------------------
f) Place of the transaction London Stock Exchange main market
--- ----------------------------------------- ----------------------------------------------------------------------
**ENDS**
For further information, please visit the Group's website
www.widecellsgroup.com, follow us on Twitter @WideCells_Group or
contact:
WideCells Group CEO - João Andrade Tel: +351 919
PLC 033 171
------------------- ------------------------- --------------
Smaller Company Broker - Jeremy Woodgate Tel: +44 (0)
Capital Limited & Rupert Williams 20 3651 2912
------------------- ------------------------- --------------
Shard Capital Broker - Damon Heath Tel: +44 (0)
Partners LLP & Erik Woolgar 20 7186 9950
------------------- ------------------------- --------------
St Brides Partners PR - Charlotte Page Tel: +44 (0)
Limited & Isabel de Salis 20 7236 1177
------------------- ------------------------- --------------
Notes to Editors
WideCells Group PLC
WideCells Group PLC is building an integrated stem cell services
company, focused on making stem cell treatments accessible and
affordable. This is achieved through three divisions:
The Group has three divisions:
-- CellPlan: the world's first stem cell healthcare insurance
plan with financial cover for medical treatment, travel and
accommodation expenses and concierge service to manage the
treatment process.
-- WideCells: The Institute of Stem Cell Technology has been
established and is based in the University of Manchester Innovation
Centre to provide stem cell storage services and focus on stem cell
research and regenerative medicine. Its international cryogenics
division specialises in stem cell storage, with the Group currently
offering umbilical cord blood and tissue storage services to
clients in the UK and Europe under the brand name BabyCells.
-- Wideacademy: an education and training division to promote
awareness of the benefits of stem cell storage across the global
general practice community.
The Group has built an experienced senior management team that
has been integral to the development of its growth and business to
date.
Stem Cell Fast Facts:
-- Cord blood (which is taken from the umbilical cord) provides
the most effective source of stem cells for families due to it
being simple, safe and painless to collect relative to other
sources of stem cells such as bone marrow - WideCells will focus on
promoting the collection and storage of cord blood.
-- Since 2005, there has been a 300% increase in the number of
illnesses that can be treated using stem cells.
-- 82 illnesses can currently be treated using stem cell procedures.
-- Despite initial storage often costing no more than a few
GBPthousand, actual treatment can cost in the GBPhundreds of
thousands
This announcement contains inside information for the purposes
of Article 7 of the Market Abuse Regulation (EU) 596/2014 (MAR). On
publication of this announcement, this inside information is now
considered to be in the public domain.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ROMLIFLARDITFIT
(END) Dow Jones Newswires
June 28, 2018 05:30 ET (09:30 GMT)
Iconic Labs (LSE:ICON)
Historical Stock Chart
From Apr 2024 to May 2024
Iconic Labs (LSE:ICON)
Historical Stock Chart
From May 2023 to May 2024